Grants and Contributions:
Title:
Route of Administration and Preclinical Efficacy of Gene Therapy
Agreement Number:
952759
Agreement Value:
$132,000.00
Agreement Date:
Jun 1, 2020 - Mar 22, 2021
Description:
This project will involve determining optimal route of administration of Transfection Competent Vesicle (TCV) delivery of gene editing machinery in vivo efficacy studies to generate critical proof of concept data, advance internal drug development and initiate possible pharma partnering opportunities.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6S 1Z3
Reference Number:
172-2020-2021-Q2-952759
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
758555288
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is -10,000 dollars.
Amendment Date
Mar 17, 2021
Recipient's Legal Name:
Incisive Genetics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: